Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Myeloid, Acute 9Leukemia 8Hematologic Neoplasms 7Lymphoma, Non-Hodgkin 6Lymphoma 6Multiple Myeloma 4Primary Immunodeficiency Diseases 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Neoplasm, Residual 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hemoglobinopathies 2Fanconi Anemia 2Cytokine Release Syndrome 2Breast Neoplasms 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thymoma 1

Interventions

Rituximab 9Cyclophosphamide 8fludarabine 5dacetuzumab 5blinatumomab 5Brentuximab Vedotin 4Bendamustine Hydrochloride 4ibrutinib 3fludarabine phosphate 3Vincristine 3Prednisone 3Melphalan 3Etoposide 3Doxorubicin 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lutetium 2Ifosfamide 2Everolimus 2Cytarabine 2Carboplatin 2Busulfan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphatic Diseases × AP 1903 reagent × Clear all
NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡